The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II study of sorafenib in patients with metastatic or unresectable gastrointestinal stromal tumors with failure of both imatinib and sunitinib: A KGSG study.
M. Ryu
No relevant relationships to disclose
S. H. Park
No relevant relationships to disclose
B. Ryoo
No relevant relationships to disclose
S. Im
No relevant relationships to disclose
H. Kwon
No relevant relationships to disclose
S. S. Lee
No relevant relationships to disclose
S. R. Park
No relevant relationships to disclose
B. W. Kang
No relevant relationships to disclose
Y. Kang
Consultant or Advisory Role - Bayer
Honoraria - Bayer
Research Funding - Bayer